CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies

Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR(+) T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood. To shed light on this issue,...

Descripción completa

Detalles Bibliográficos
Autores principales: Louie, Raymond Hall Yip, Cai, Curtis, Samir, Jerome, Singh, Mandeep, Deveson, Ira W., Ferguson, James M., Amos, Timothy G., McGuire, Helen Marie, Gowrishankar, Kavitha, Adikari, Thiruni, Balderas, Robert, Bonomi, Martina, Ruella, Marco, Bishop, David, Gottlieb, David, Blyth, Emily, Micklethwaite, Kenneth, Luciani, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682404/
https://www.ncbi.nlm.nih.gov/pubmed/38012187
http://dx.doi.org/10.1038/s41467-023-43656-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682404/
https://www.ncbi.nlm.nih.gov/pubmed/38012187
http://dx.doi.org/10.1038/s41467-023-43656-7

Ejemplares similares